

POSTER PRESENTATION

Open Access

0.045% DAC N-055 a choice for poor Afghan surgical patients?

KW Stahl^{1*}, H Darmangar²

From International Conference on Prevention & Infection Control (ICPIC 2011)
Geneva, Switzerland. 29 June – 2 July 2011

Introduction / objectives

O₂ enriched pharmaceutical chlorite [NaClO₂ German Drug Codex monograph DAC N-055, 1990] contains Na₂Cl₂O₆ formerly called TCDO, (NaClO₂)₄·O₂ fights tissue infections and promotes wound granulation of radiogenic ulcers [http://www-pub.iaea.org/mtcd/publications/pdf/te_1300_web.pdf]. Under our hygienic conditions the intra- and postoperative topical use of 0.045% DAC N-055 helps us to deal with bone & tissue infections in orthopaedic surgery in Mazar. Here we document 4 cases out of the total number of 26 patients, we monitored in the former Military Hospital in Mazar 2004 - 2006 to familiarize ourselves with this German drug first registered as Oxoferin[®] in 1983.

Methods

The speed of ¹ClO₂ release from 0.045 % DAC N-055 (max. 160 ppm) increases with decreasing pH. ¹ClO₂ induces no resistance. In all patients the field of surgical intervention is rinsed several times with 0.045 % DAC N-055 in saline especially during the operation, especially before wound closure and dressed with cotton gauzes kept moist till the patient is discharged home. Post-OP irrigations are practised with 0.045 % DAC N-055 for septic arthritis (closed method) and osteomyelitis (open method).

Results

1/2 septic arthritis, osteomyelitis cases and 2/22 osteomyelitis cases are photo-documented. Without antibiotics, septic arthritis had an excellent functional outcome after 6 weeks, the open fracture with skin defect received mesh graft on excellent granulation after 1 month and was completely closed after 3 months. 11/22 osteomyelitis cases could be monitored for 6 to 18

months, 6 cases relapsed within this time, for 8/11 patients antibiotics were not available.

Conclusion

If 4.5% DAC N-055 could be sold in Afghanistan at 50% of the price of the finished drug Oxoferin[®] sold in Pakistan this could help poor patients in traumatology.

Disclosure of interest

None declared.

Author details

¹Waisenmedizin E. V., Freiburg i. Brsg., Germany. ²Medical Faculty, Balkh University, Mazar-e-Sharif, Afghanistan.

Published: 29 June 2011

doi:10.1186/1753-6561-5-S6-P246

Cite this article as: Stahl and Darmangar: 0.045% DAC N-055 a choice for poor Afghan surgical patients? *BMC Proceedings* 2011 **5**(Suppl 6):P246.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Waisenmedizin E. V., Freiburg i. Brsg., Germany
Full list of author information is available at the end of the article